Registered outcomes12

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 12 of 12

List	Outcome	Time frame	Description
Primary	Number of Participants with a Dose Limiting Toxicity (DLT)	24 months
Primary	Number of Participants with Treatment-emergent Adverse Events (TEAE)	24 months
Primary	Number of Participants with Treatment-related Adverse Events	24 months
Primary	Number of Participants with Clinically Significant Changes in Vital Signs	24 months
Primary	Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Measurements	24 months
Primary	Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests	24 months
Secondary	6-month Progression-free Survival (PFS)	24 months
Secondary	Objective Response (OR)	24 months	Per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Secondary	Duration of Response (DOR)	24 months
Secondary	Disease Control Rate(DCR)	24 months
Secondary	Overall Survival (OS)	24 months
Secondary	Serum Concentration of Tarlatamab	24 months

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05361395/registered